Trip.com Group Ltd vs Health Care Select Sector SPDR Fund — how do they compare? Trip.com Group Ltd trades at $45.65 (market cap $29.26B), while Health Care Select Sector SPDR Fund trades at $167.94. The key difference: Trip.com Group Ltd pays a 0.42% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Trip.com Group Ltd nearer its low. Which is the better fit depends on your goals.
| TCOM | XLV | |
|---|---|---|
Market Cap | $29.26B | — |
Sector | Consumer Cyclical | — |
52-Week High | $78.96 | $168.44 |
52-Week Low | $39.84 | $131.16 |
Enterprise Value | $21.91B | — |
Dividend Yield | 0.42% | — |
Signals from Pluang's Aura AI — not financial advice
TCOM trades at $46.14, down 0.22% on the day, with a neutral technical signal and bearish moving averages. The company reported strong 2025 revenue of $62.41B and net income of $33.29B, with high profitability margins. Recent news includes a $770M antitrust penalty in China, impacting sentiment, while Q2 2026 earnings are expected at $0.873 per share.
Outlook remains mixed: strong fundamentals and a consensus price target of $59.29 suggest upside, but regulatory risks and recent earnings misses pose challenges. The stock offers value with a low P/E of 6.88, yet investors must weigh growth sustainability against antitrust pressures and guidance concerns.
XLV trades at $165.68, up 0.75% with a bullish technical signal from moving averages. The healthcare ETF shows strong defensive positioning amid market volatility, with recent articles highlighting its cost efficiency at 0.08% expense ratio and $41.7 billion AUM. Technical indicators show support at $164 and resistance at $167, with RSI levels in neutral territory suggesting balanced momentum.
The outlook remains positive given healthcare's defensive characteristics and recent sector inflows. Key risks include regulatory pressures and competitive ETF offerings, but XLV's diversification across 60 healthcare stocks provides stability. Analyst comparisons favor XLV for lower costs and steady performance versus specialized biotech ETFs.
Trailing returns across standard periods
Latest headlines on both assets
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →